@article{de:2026:10.1016/S2213-2600(26)00082-2,
author = {de, Benedictis FM and Beasley, R and Pavord, I and Szefler, SJ and Zar, HJ and Bush, A},
doi = {10.1016/S2213-2600(26)00082-2},
journal = {Lancet Respir Med},
title = {50 years on: how inhaled corticosteroids have changed the treatment of asthma.},
url = {http://dx.doi.org/10.1016/S2213-2600(26)00082-2},
year = {2026}
}

Download

TY  - JOUR
AB  - Inhaled corticosteroids are the foundation of asthma therapy and now, 50 years on from their introduction, is an appropriate time to summarise some of the key studies that have progressed the field. We can now make better decisions in selecting the optimal inhaled corticosteroid-based regimens and identifying likely responders, based on biomarkers and patient characteristics. Inhaled corticosteroids reduce the risk of asthma attacks, but do not alter the course of the disease. Asthma remission, which is as yet an undefined therapeutic goal, is the aim, but the role of inhaled corticosteroids is unclear. High-dose inhaled corticosteroid therapy can cause systemic adverse events, suggesting that steps be taken to avoid this through the addition of long-acting β2-adrenergic agonists and the judicious use of biologics. Researchers will continue to learn more about the advantages and limitations of inhaled corticosteroids as they explore methods of disease prevention and remission in the future with new tools and treatments.
AU  - de,Benedictis FM
AU  - Beasley,R
AU  - Pavord,I
AU  - Szefler,SJ
AU  - Zar,HJ
AU  - Bush,A
DO  - 10.1016/S2213-2600(26)00082-2
PY  - 2026///
TI  - 50 years on: how inhaled corticosteroids have changed the treatment of asthma.
T2  - Lancet Respir Med
UR  - http://dx.doi.org/10.1016/S2213-2600(26)00082-2
UR  - https://www.ncbi.nlm.nih.gov/pubmed/42107381
ER  - 

Download